Elevated pressure inside the eye, cornea thinning, and visual field loss are all markers that glaucoma may progress, according to a report in the May issue of Archives of Ophthalmology, one of the JAMA/Archives journals. Glaucoma is one of the world…
Author: Medical News Today
Belfast Experts Tackling Baby Blindness, UK
Two teams of experts in Belfast are working to help stop the suffering of thousands of babies1 affected by a condition which causes blindness, thanks to funding from Sussex-based children’s charity Action Medical Research…
Belfast Experts Tackling Baby Blindness, UK
Two teams of experts in Belfast are working to help stop the suffering of thousands of babies1 affected by a condition which causes blindness, thanks to funding from Sussex-based children’s charity Action Medical Research…
The Brain Performs Visual Search Near Optimally
In the wild, mammals survive because they can see and evade predators lurking in the shadowy bushes. That ability translates to the human world. Transportation Security Administration screeners can pick out dangerous objects in an image of our messy an…
The Brain Performs Visual Search Near Optimally
In the wild, mammals survive because they can see and evade predators lurking in the shadowy bushes. That ability translates to the human world. Transportation Security Administration screeners can pick out dangerous objects in an image of our messy an…
Bayer And Regeneron Report Positive Results For VEGF Trap-Eye In Second Phase 3 Study In Central Retinal Vein Occlusion
Bayer HealthCare and Regeneron Pharmaceuticals, Inc. announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the Phase 3 GALILEO study in patients with macular edema due to central retinal vein occlusion (CRVO). The p…
Bayer And Regeneron Report Positive Results For VEGF Trap-Eye In Second Phase 3 Study In Central Retinal Vein Occlusion
Bayer HealthCare and Regeneron Pharmaceuticals, Inc. announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the Phase 3 GALILEO study in patients with macular edema due to central retinal vein occlusion (CRVO). The p…
Physicist Is Leading Effort To Design Fractal Devices – Nanoflowers – To Help Return Eyesight
University of Oregon researcher Richard Taylor is on a quest to grow flowers that will help people who have lost their sight, such as those suffering from macular degeneration, to see again. These flowers are not roses, tulips or columbines. They will …
Physicist Is Leading Effort To Design Fractal Devices – Nanoflowers – To Help Return Eyesight
University of Oregon researcher Richard Taylor is on a quest to grow flowers that will help people who have lost their sight, such as those suffering from macular degeneration, to see again. These flowers are not roses, tulips or columbines. They will …
Promedior Announces Presentation Of Preclinical Data At ARVO Demonstrating PRM-151 (rhPTX-2) Reduces Neovascularization In Retinal Diseases
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, announced that data from preclinical studies of PRM-151 (recombinant human Pentraxin-2 (PTX-2)) were presented …
Promedior Announces Presentation Of Preclinical Data At ARVO Demonstrating PRM-151 (rhPTX-2) Reduces Neovascularization In Retinal Diseases
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, announced that data from preclinical studies of PRM-151 (recombinant human Pentraxin-2 (PTX-2)) were presented …
Phase 2 Clinical Trial Data Of UF-021 In Retinitis Pigmentosa Patients Presented At ARVO 2011
Sucampo Pharmaceuticals, Inc. (“Sucampo”), (NASDAQ: SCMP) today reported data from a proof of concept phase 2 clinical trial conducted by R-Tech Ueno, Ltd. (“RTU”, JASDAQ: 4573), of UF-021 (unoprostone isopropyl) in 112 patients with retinitis pigmento…
Phase 2 Clinical Trial Data Of UF-021 In Retinitis Pigmentosa Patients Presented At ARVO 2011
Sucampo Pharmaceuticals, Inc. (“Sucampo”), (NASDAQ: SCMP) today reported data from a proof of concept phase 2 clinical trial conducted by R-Tech Ueno, Ltd. (“RTU”, JASDAQ: 4573), of UF-021 (unoprostone isopropyl) in 112 patients with retinitis pigmento…
Study Demonstrates Benefits Of MicroPulse™ Photocoagulation Over Current Standard Laser Treatment Of Diabetic Macular Edema
IRIDEX Corporation (Nasdaq: IRIX) announced that leading clinicians have performed and published the results of a new study* that compares the benefits of MicroPulse photocoagulation technology, similar to that used in the new generation IRIDEX lasers,…
Study Demonstrates Benefits Of MicroPulse™ Photocoagulation Over Current Standard Laser Treatment Of Diabetic Macular Edema
IRIDEX Corporation (Nasdaq: IRIX) announced that leading clinicians have performed and published the results of a new study* that compares the benefits of MicroPulse photocoagulation technology, similar to that used in the new generation IRIDEX lasers,…
Study Demonstrates Electrical Stimulation Therapy Safe And Well-Tolerated In Early Stage Retinitis Pigmentosa Patients
Okuvision GmbH, an innovator in the field of electrical stimulation therapy (EST) for early and intermediate stage retinitis pigmentosa patients, today announced the presentation of data from the company’s first sham-controlled pilot study at the Assoc…
Study Demonstrates Electrical Stimulation Therapy Safe And Well-Tolerated In Early Stage Retinitis Pigmentosa Patients
Okuvision GmbH, an innovator in the field of electrical stimulation therapy (EST) for early and intermediate stage retinitis pigmentosa patients, today announced the presentation of data from the company’s first sham-controlled pilot study at the Assoc…
PSivida Announces New Safety And Efficacy Data From Phase 3 Study Of ILUVIEN(R) In Diabetic Macular Edema
pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the presentation of new data from the completed 36-month FAME™ Study of ILUVIEN for th…
PSivida Announces New Safety And Efficacy Data From Phase 3 Study Of ILUVIEN(R) In Diabetic Macular Edema
pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the presentation of new data from the completed 36-month FAME™ Study of ILUVIEN for th…
Second Sight Announces Significant Results From The Argus™ II Retinal Prosthesis Trial At The ARVO 2011 Annual Meeting
Exciting results from the Argus™ II Retinal Prosthesis System (‘Argus II’) clinical trial were presented today at the Association for Research in Vision and Ophthalmology, Inc. (ARVO) 2011 Annual Meeting. The clinical trial included 30 subjects impla…